Objective: This study aimed to evaluate the prevalence of antiphospholipid syndrome (APS) among women experiencing recurrent pregnancy loss (RPL). Methods: A cross-sectional was conducted, reviewing ...

When scientists engineer a better way to fight the flu, they often begin with nature’s own defenses. That’s what a new study from researchers at The Ohio State University set out to do. Their goal was ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...

IGM Biosciences, Inc. is halting the development of its bispecific antibodies imvotamab and IGM-2644 due to insufficient data from clinical trials, specifically regarding B cell depletion for treating ...

Background: Antiphospholipid antibodies (aPL) trigger inflammation, vasculopathy, and thrombosis, sharing pathophysiological mechanisms with atherosclerosis. However, their association with incident ...

Staphylococcus aureus, mostly known from its antibiotic-resistant variant Methicillin-resistant Staphylococcus aureus (MRSA), is among the leading causes of both community- and hospital-acquired ...

Hepatitis A blood tests check for immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. An IgG-positive and IgM-negative result may suggest immunity to hepatitis A. A doctor may request a ...

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...

Sanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three IgM agonist antibodies for immunology and inflammation and shed three ...

Fetal-maternal outcomes were comparable between patients with low-titer and medium-high titer positivity for antiphospholipid antibodies, following appropriate treatment. Fetal-maternal outcomes were ...